Skip to content
DraconiticResearch
Search Sources API
197,693 studies31 sourcesUpdated 15 min ago
Peer-reviewedCC BYDiseases (Basel, Switzerland)

Exploratory Comparison of Routine Inflammatory Biomarkers in Nasopharyngeal Carcinoma and Benign Adenoid-Associated Pathology.

  • Darius Radu Roman1
  • Carmen Delia Nistor Cseppento2
  • Dana Carmen Zaha3
  • Timea Claudia Ghitea4
  • Alexia Manole5
  • Dana Zdremtan6
  • Alexandru Chioreanu6
  • Felicia Manole7
7 affiliations
  1. 1Doctoral School of Biomedical Sciences, Faculty of Medicine and Pharmacy, University of Oradea, 410087 Oradea, Romania.
  2. 2Department of Psycho-Neuroscience and Recovery, Faculty of Medicine and Pharmacy, University of Oradea, 410073 Oradea, Romania.
  3. 3Department of Preclinical Disciplines, Faculty of Medicine and Pharmacy, University of Oradea, 410073 Oradea, Romania.
  4. 4Department of Pharmacy, Faculty of Medicine and Pharmacy, University of Oradea, 410073 Oradea, Romania.
  5. 5Faculty of Medicine and Pharmacy, University of Oradea, 410068 Oradea, Romania.
  6. 6Department of Biochemistry, "Vasile Goldis" Western University, B-dul Revolutiei Nr. 96, 310025 Arad, Romania.
  7. 7Medicine Department, Faculty of Medicine and Pharmacy, University of Oradea, 410068 Oradea, Romania.
Read full textPDFDOICite

Abstract

Background

Nasopharyngeal carcinoma (NPC) may be accompanied by systemic inflammatory changes, but routine inflammatory markers are nonspecific and have not been validated as diagnostic tests for NPC.Methods

This exploratory retrospective comparison screened 178 adults and included 72 eligible records (36 histopathologically confirmed NPC and 36 histologically confirmed benign adenoid-associated pathology); 106 records were excluded because of incomplete endoscopic or laboratory records (n = 41), hematological malignancy (n = 15), severe hepatic failure (n = 11), or a documented systemic inflammatory condition unrelated to the nasopharyngeal presentation (n = 39). CRP, erythrocyte sedimentation rate (ESR), leukocyte count, selected biochemical variables, and an investigator-derived loco-regional clinical/endoscopic severity score were compared. Prespecified sensitivity analyses included age- and sex-adjusted rank regression, restriction to the overlapping age range (39-52 years), group-stratified correlations, and partial rank correlations adjusted for diagnostic group, age, and sex.Results

The NPC group was younger than the benign group (38.1 ± 7.6 vs. 56.1 ± 8.3 years; p < 0.001). CRP, ESR, leukocyte count, uric acid, and the loco-regional score were higher in the NPC group (all p < 0.01). The principal differences persisted in the overlapping-age subset (NPC n = 17; benign n = 16; all p < 0.001) and in age- and sex-adjusted rank analyses. Pooled correlations were attenuated or changed after stratification and covariate adjustment, indicating that part of the pooled association reflected between-group separation. Exploratory ROC AUCs were 1.000 for CRP, leukocyte count, and the loco-regional score and 0.948 for ESR; these values were derived and evaluated in the same selected cohort. In separate Firth models adjusted for age and sex, CRP, leukocyte count, and the loco-regional score remained associated with NPC, whereas ESR did not (p = 0.200).Conclusions

The study identifies marked between-group differences in this selected retrospective cohort but does not establish diagnostic biomarkers or clinical cut-offs. Independent prospective evaluation, standardized sampling, and fuller control of inflammatory and tumor-related confounding are required.

Related

  1. Exploratory predictive value of novel inflammatory biomarkers for microvascular obstruction after emergency revascularization in STEMI patients
    Yang Dai, Longjin Chen, Zhe Zhang +6
    Frontiers in MedicinePeer-reviewedCC BY 4.0Full textOncologyPMC
  2. Exploring Relationships Between Multimodal Lifestyle Factors, Inflammatory Biomarkers, and Pain Processing in Women with Fibromyalgia: An Exploratory Pilot Study
    Ömer Elma, Christopher Long, Amber Brown +9
    NutrientsPeer-reviewedCC BY 4.0Psychiatry & mental healthCrossref
  3. Exploratory Identification of Potential Serum Biomarkers Associated with Relapse in Multiple Myeloma.
    Wittawat Chantkran, Chonlada Laoruangroj, Sittiruk Roytrakul +4
    Diseases (Basel, Switzerland)Peer-reviewedCC BYFull textGeneral medicineEurope PMC
  4. Smoking exposure and overall survival in nasopharyngeal carcinoma: a multicenter cohort from non-endemic northern China with an exploratory meta-analysis
    Qi An, Yubing Qian, Jiaming Zhang +7
    Scientific ReportsPeer-reviewedCC BY-NC-ND 4.0Full textGeneral medicineCrossref
  5. Sex and stage-defined exploratory inflammatory and amyloid-associated readout patterns in female APP/PS1 mice exposed to TAK-242.
    Xiaolu Ren, Ting Li, Shan Liu +2
    Frontiers in aging neurosciencePeer-reviewedCC BYFull textPhysiologyEurope PMCPMC

Cite

BibTeXRIS
BibTeX
@article{roman2026exploratory,
  title = {{Exploratory Comparison of Routine Inflammatory Biomarkers in Nasopharyngeal Carcinoma and Benign Adenoid-Associated Pathology.}},
  author = {Darius Radu Roman and Carmen Delia Nistor Cseppento and Dana Carmen Zaha and Timea Claudia Ghitea and Alexia Manole and Dana Zdremtan and Alexandru Chioreanu and Felicia Manole},
  journal = {Diseases (Basel, Switzerland)},
  year = {2026},
  month = oct,
  doi = {10.3390/diseases14100365},
  url = {https://europepmc.org/article/MED/42929992},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Exploratory Comparison of Routine Inflammatory Biomarkers in Nasopharyngeal Carcinoma and Benign Adenoid-Associated Pathology.
AU  - Darius Radu Roman
AU  - Carmen Delia Nistor Cseppento
AU  - Dana Carmen Zaha
AU  - Timea Claudia Ghitea
AU  - Alexia Manole
AU  - Dana Zdremtan
AU  - Alexandru Chioreanu
AU  - Felicia Manole
PY  - 2026
DA  - 2026/10/02
JO  - Diseases (Basel, Switzerland)
DO  - 10.3390/diseases14100365
UR  - https://europepmc.org/article/MED/42929992
AB  - Background  Nasopharyngeal carcinoma (NPC) may be accompanied by systemic inflammatory changes, but routine inflammatory markers are nonspecific and have not been validated as diagnostic tests for NPC.Methods  This exploratory retrospective comparison screened 178 adults and included 72 eligible records (36 histopathologically confirmed NPC and 36 histologically confirmed benign adenoid-associated pathology); 106 records were excluded because of incomplete endoscopic or laboratory records (n = 41), hematological malignancy (n = 15), severe hepatic failure (n = 11), or a documented systemic inflammatory condition unrelated to the nasopharyngeal presentation (n = 39). CRP, erythrocyte sedimentation rate (ESR), leukocyte count, selected biochemical variables, and an investigator-derived loco-regional clinical/endoscopic severity score were compared. Prespecified sensitivity analyses included age- and sex-adjusted rank regression, restriction to the overlapping age range (39-52 years), group-stratified correlations, and partial rank correlations adjusted for diagnostic group, age, and sex.Results  The NPC group was younger than the benign group (38.1 ± 7.6 vs. 56.1 ± 8.3 years; p < 0.001). CRP, ESR, leukocyte count, uric acid, and the loco-regional score were higher in the NPC group (all p < 0.01). The principal differences persisted in the overlapping-age subset (NPC n = 17; benign n = 16; all p < 0.001) and in age- and sex-adjusted rank analyses. Pooled correlations were attenuated or changed after stratification and covariate adjustment, indicating that part of the pooled association reflected between-group separation. Exploratory ROC AUCs were 1.000 for CRP, leukocyte count, and the loco-regional score and 0.948 for ESR; these values were derived and evaluated in the same selected cohort. In separate Firth models adjusted for age and sex, CRP, leukocyte count, and the loco-regional score remained associated with NPC, whereas ESR did not (p = 0.200).Conclusions  The study identifies marked between-group differences in this selected retrospective cohort but does not establish diagnostic biomarkers or clinical cut-offs. Independent prospective evaluation, standardized sampling, and fuller control of inflammatory and tumor-related confounding are required.
SN  - 2079-9721
ER  -